Measured improvement across all Sustainability Pillars

The 14-point overall increase was driven by significant performance gains in all four EcoVadis assessment areas:

Environmental Management: +16 Points (70 → 86). Our Environmental score increased by 16 points, reflecting strengthened environmental governance, measurable KPIs, emissions management, waste control systems, and compliance aligned with pharmaceutical manufacturing standards in Europe and international markets.

Labor & Human Rights: +13 Points (70 → 83). The 13-point improvement demonstrates the maturity of documented labor policies, occupational health and safety systems, employee development frameworks, and structured evidence of implementation across operations.

Ethics & Compliance: +9 Points (70 → 79). Reinforced compliance mechanisms, anti-corruption controls, governance accountability, and internal oversight systems supported the advancement in ethical performance.

Sustainable Procurement: +24 Points (60 → 84). The most significant improvement was achieved in Sustainable Procurement, with a 24-point increase.

This reflects structured supplier ESG onboarding, risk-based segmentation, monitoring mechanisms, and the integration of sustainability criteria into pharmaceutical API supply chain management. For regulated pharmaceutical markets, this pillar is particularly relevant, as supply chain governance is a critical determinant of operational and reputational risk.

An evidence-based assessment

The evaluation was conducted according to the internationally recognized EcoVadis sustainability rating methodology, based on 21 criteria aligned with UN Global Compact principles, ISO standards, and GRI guidelines. EcoVadis contextualizes assessment results according to sector and country risk exposure, benchmarking companies against global peers.

Our progression from 69 to 83 confirms the structural integration of ESG principles into daily operations, compliance systems, and supply chain management.

Why this matters for Pharmaceutical Procurement Teams

In European and global pharmaceutical markets, ESG performance is increasingly embedded into supplier qualification processes.

A 14-point improvement and placement within the Top 5% worldwide provides:

• Reduced supply chain sustainability risk

• Greater transparency and governance maturity

• Alignment with EU ESG and due diligence expectations

• Strengthened regulatory readiness in regulated markets

Sustainability performance is no longer a reputational layer — it is a procurement filter.

Frequently Asked Questions

What does a +14 point EcoVadis increase indicate? A double-digit score increase within one assessment cycle indicates structural improvements in governance, documentation, implementation evidence, and measurable performance.

How does a +24 point increase in Sustainable Procurement reduce supply chain risk? It reflects formalized supplier ESG integration, monitoring systems, and risk-based segmentation, which reduce exposure to operational, regulatory, and reputational disruptions.

Is EcoVadis Gold relevant for pharmaceutical companies? Yes. ESG screening, supply chain due diligence, and regulatory transparency requirements across the EU make third-party sustainability verification increasingly relevant in supplier qualification processes.

How does ESG maturity impact API manufacturing partnerships? Higher ESG maturity supports regulatory readiness, operational resilience, and long-term reliability — critical factors in pharmaceutical manufacturing relationships.

Partner with a Top 5% ESG-Rated Pharmaceutical Manufacturer

As a European pharmaceutical API manufacturer serving global markets, UQUIFA integrates sustainability into its operational model and long-term strategy. Pharmaceutical companies seeking a low-risk, ESG-aligned manufacturing partner can request detailed sustainability documentation and performance data.

→ Speak with our Sales or CDMO Teams

To verify our Ecovadis Recognition, please visit this microsite